Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor - EP3324956

The patent EP3324956 was granted to Anavex Life Sciences on Nov 20, 2024. The application was originally filed on Jul 19, 2016 under application number EP16827322A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3324956

ANAVEX LIFE SCIENCES
Application Number
EP16827322A
Filing Date
Jul 19, 2016
Status
Granted And Under Opposition
Oct 18, 2024
Grant Date
Nov 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJun 12, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2011206780
DESCRIPTIONUS5034419
DESCRIPTIONWO2013008044
DESCRIPTIONWO2014155138
DESCRIPTIONWO9730983
INTERNATIONAL-SEARCH-REPORTWO9730983
OPPOSITIONWO2013008044
OPPOSITIONWO2014155138
OPPOSITIONWO9730983
SEARCHWO2014155138

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Lien Ai Nguyen, He, Hua; Pham-Huy, Chuong, "Chiral drugs: an overview", International Journal of Biomedical Science, US , (20060601), vol. 2, no. 2, ISSN 1550-9702, pages 85 - 100, XP055377728-
OPPOSITION- MACH ROBERT H ET AL, "Sigma-2 Receptors as potential biomarkers of proliferation in breast cancer.", Cancer Research, (19970101), vol. 57, no. 1, ISSN 0008-5472, pages 156 - 161, XP002154194-
OPPOSITION- Reagan-Shaw S, Nihal M, Nihal N, "Dose translation from animal to human studies revisited", The FASEB Journal, US, (20070101), vol. 22, ISSN 0892-6638, pages 659 - 661, XP007916336-
OPPOSITION- Macfarlane Stephen; Cecchi Marco; Moore Dennis; Zografidis Tasos; Missling Christopher, "P4-300 New exploratory Alzheimer’s drug anavex 2-73 changes in electrophysiological markers in Alzheimer’s disease: First patient data from an ongoing phase 2a study in mild-to-moderate Alzheimer’s patients", Alzheimer's & Dementia, US , (20150101), vol. 11, no. 7, doi:10.1016/j.jalz.2015.08.130, ISSN 1552-5260, page P900, XP029355199
OPPOSITION- Valentine Lahmy, Johann Meunier, Susanna Malmström, Gaelle Naert, Laurent Givalois, Seung Hyun Kim, Vanessa Villard, Alexandre Vamvakides, Tangui Maurice, "Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease", Neuropsychopharmacology, Cham, (20130801), vol. 38, no. 9, doi:10.1038/npp.2013.70, ISSN 0893-133X, pages 1706 - 1723, XP055300697
OPPOSITION- AL-NABUISI I, "EFFECT OF PLOIDY, RECRUITMENT, ENVIRONMENTAL FACTORS, AND TAMOXIFENTREATMENT ON THE EXPRESSION OF SIGMA-2 RECEPTORS IN PROLIFERATING AND QUIESCENT TUMOUR CELLS", British Journal of Cancer, London, (19990101), vol. 81, no. 06, doi:10.1038/sj.bjc.6690789, ISSN 0007-0920, pages 925 - 933, XP002946868
OPPOSITION- WHEELER K T, "Sigma-2 receptors as a biomarker of proliferation in solid tumours", British Journal of Cancer, London, (20000101), vol. 82, no. 06, doi:10.1054/bjoc.1999.1067, ISSN 0007-0920, pages 1223 - 1232, XP002946867
OPPOSITION- Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Vamvakides, Alexandre; Maurice, Tangui, "Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (.sigma.1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative", Journal of psychopharmacology, GB , (20110101), vol. 25, no. 8, doi:10.1177/0269881110379286, ISSN 0269-8811, pages 1101 - 1117, XP009169910
OPPOSITION- Simona Collina, Raffaella Gaggeri, Annamaria Marra, Andrea Bassi, Sara Negrinotti, Francesca Negri, Daniela Rossi, "Sigma receptor modulators: a patent review", Expert opinion on therapeutic patients, GB , (20130501), vol. 23, no. 5, doi:10.1517/13543776.2013.769522, ISSN 1354-3776, pages 597 - 613, XP055538759
OPPOSITION- Bentham Science Publisher Bentham Science Publisher, "Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals", Current Pharmaceutical Design, (20061001), vol. 12, no. 30, doi:10.2174/138161206778559614, ISSN 1381-6128, pages 3857 - 3876, XP055107718
OPPOSITION- Valentine Lahmy , Romain Long , Didier Morin, Vanessa Villard , Tangui Maurice, "Mitochondrial protection by the mixed muscarinic/[sigma]1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A[beta]25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.", Frontiers Research Foundation, CH , (20150120), vol. 8, no. 463, doi:10.3389/fncel.2014.00463, ISSN 1662-5102, pages 1 - 11, XP002761608
SEARCH- MACFARLANE STEPHEN ET AL, "New exploratory Alzheimer's drug anavex 2-73 changes in electrophysiological markers in Alzheimer's disease: First patient data from an ongoing phase 2a study in mild-to-moderate Alzheimer's patients", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, (201507), vol. 11, no. 7, doi:10.1016/J.JALZ.2015.08.130, ISSN 1552-5260, XP029355199 [I] 1-10 * abstract *
SEARCH- SIMONA COLLINA ET AL, "Sigma receptor modulators: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, (20130207), vol. 23, no. 5, doi:10.1517/13543776.2013.769522, ISSN 1354-3776, pages 597 - 613, XP055538759 [I] 1-10 * page 609 - page 610 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents